SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2002 / Cilt: 36 - Sayı: 3

Clinical stating and results of therapy in patients with Mycosis fungoides

Mikozis fungoides olgularında klinik evrelendirme ve tedavi sonuçlarıyla ilişkisi

Hayriye SARICAOĞLU
Şükran TUNALI
Kenan AYDOĞAN
Fahir ÖZKALEMKAŞ
Rıdvan ALİ
Ahmet TUNALI
Pages
197–200
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: The results of study, which has shown that 62.5% of cases applied to our clinic in stage I B, supports the idea of better clinical response in eraly stages as well

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Mycosis Fungoides is the most common primary skin lymphoma and clinical stating of this disease is very important for determination of the treatment and prognosis.
📊
Key Findings & Data:Method: The clinical signs of 16 patients, aged between 44 and 60, who had been followed from November 1987 to May 1997 in Uludağ University Medical Faculty with a diagnosiss of Mycosis Fungoides were reviewed.
💡
Conclusion & Impact:Conclusions: The results of study, which has shown that 62.5% of cases applied to our clinic in stage I B, supports the idea of better clinical response in eraly stages as well
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Mycosis Fungoides is the most common primary skin lymphoma and clinical stating of this disease is very important for determination of the treatment and prognosis. Method: The clinical signs of 16 patients, aged between 44 and 60, who had been followed from November 1987 to May 1997 in Uludağ University Medical Faculty with a diagnosiss of Mycosis Fungoides were reviewed. Result: Ten of the patients were in stage IB, 1 in II A, 3 in II B and 1 in IV B. Conclusions: The results of study, which has shown that 62.5% of cases applied to our clinic in stage I B, supports the idea of better clinical response in eraly stages as well

Özet

Kasım 1987-Mayıs 1997 tarihleri arasında Uludağ Üniversitesi Tıp Fakültesi'nde Mikozis Fungoides tanısıyla takip edilen, yaşları 44-60 arasında değişen 5'i kadın, 11 'i erkek toplam 16 hastaya ait bulgular gözden geçirildi. Biyopsi ile tanı konulduğu tarihte, mevcut lezyonların tipi, lokalizasyonu ve histopatolojik sonuçlarına göre TNM sınıflandırması ile klinik evrelendirilmeleri değerlendirildi. Buna göre, 10 hasta (%62.50) evre l B, 1 hasta (%6.25) evre II A, 3 hasta (%18.75) evre II B, 1 hasta (7.25) evre III B, 1 hasta (6.25) evre IV B olarak kabul edildi. Olguların % 62.5'unun evre l B aşamasında başvurduğunu saptadığımız çalışma sonuçlarımız, erken evrede tedaviye yanıtın daha iyi olduğu görüşlerini desteklemektedir.

🔖

Cite This Article

SARICAOĞLU, H., TUNALI, Ş., AYDOĞAN, K., ÖZKALEMKAŞ, F., ALİ, R., TUNALI, A. (2022). Clinical stating and results of therapy in patients with Mycosis fungoides. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 36 - Sayı: 3, 197–200. https://ajindex.com/articles/622294

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Diamandidou E, Cohe PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood. 1996; 88: 2385-2409
  2. Me Kie RM: Lymphomas and Leukaemias: Textbook of Dermatology. Ed. Rook A, Wilkinson DS, Ebling FJG. 5th Ed. Oxford,Blackwell Sci Pub. 1993; 2107-2134
  3. Heald PW, Edelson RL: Lymphomas, Pseudolymhomas and Related Conditions. Dermatology in General Medicine. Ed. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg İM, Ausen KF eds. 4th ed. New York, Me Graw Hill Inc., 1993; 1 285-1307
  4. Arnold HL, Odom RB, James WD: Andrews' Diseases of the Skin. Philadelphia, W.B. Saunders Comp, 1990; 854-863
  5. Willemze R, Kerl H, Sterry EB et al.: EORTC Classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the european organization for research and treatment of cancer. J Am Society of Hematology 1997; 90: 354-371
  6. Loricz AL: Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996; 347: 871-876
  7. Yavuzer R, Ertan C, Gürgey E: Mikozis fungoides'li olgularda HIV ve sitomegalovirus antikorlarının araştırılması. T Klin Dermatol 1991; 1: 1-4
  8. Braun-Falco O, Plewing G, Wolff HH, Winkelmann RK: Dermatology. 3rd ed. Berlin, Springer Verlag, 1991; 1086-1092
  9. Kim YH, Jensen RA, Watanabe GR, Vaghese A, Hoppe RT: Clinical Stage IA (limited patch and plaque) mycosis fungoides.Arch Dermatol 1996; 132: 1309-1313
  10. Erdem C, Dönderici L, Dartanel S, Şener S: Erken yaşlarda başlayan mikozis fungoides olgularının klinik ve dermatopatolojik özellikleri. Lep Mec 1991; 22: 149-156
  11. Marti RM, Estrach T, Reverter JC, Mascara JM: Prognostic clini- copathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127-1511-1516
  12. Weinstock MA, Horm JW: Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-46
  13. Bozkurt E. Mycosis fungoides'de evrelendirme: TÜRKDERM 1996; 30: 61-68
  14. Holloway KB, Flowers FP, Ramos-Caro FA: Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992;27: 367-378
  15. Ergun T, Yücelten D: Derinin T hücreli lenfomasında tedavi. TÜRKDERM 1997; 31: 94-102
  16. Kaye F, Bunn P. Steinberg S, et al: A randomized trial comparing combinitaion electron-beam radiation and chemotherapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790
  17. Koh HK, Jacobson JO, Foss F, Lew RA: Is cutaneous T-cell lymphoma curable? Arch Dermatol 1995; 131:1081 -1082.